Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery.
Nimodipine (NM) is the only FDA-approved drug for treating subarachnoid hemorrhage induced vasospasm. NM has poor oral bioavailability (5-13%) due to its low aqueous solubility, and extensive first pass metabolism. The objective of this study is to develop radiolabeled NM-loaded LPM and to test its ability prolong its circulation time, reduce its frequency of administration and eventually target it to the brain tissue. NM was radiolabeled with99mTc by direct labeling method using sodium dithionite. Different reaction conditions that affect the radiolabeling yield were studied. The in vivo pharmacokinetic behavior of the optimum NM-loaded LPM formulation in blood, heart, and brain tissue was compared with NM solution, after intravenous and intranasal administration. Results show that the radioactivity percentage (%ID/g) in the heart of mice following administration of99mTc-NM loaded LPM were lower compared with that following administration of99mTc-NM solution, which is greatly beneficial to minimize the cardiovascular side effects. Results also show that the %ID/g in the blood, and brain following intravenous administration of99mTc-NM-loaded LPM were higher at all sampling intervals compared with that following intravenous administration of99mTc-NM solution. This would be greatly beneficial for the treatment of neurovascular diseases. The drug-targeting efficiency of NM to the brain after intranasal administration was calculated to be 1872.82%. The significant increase in drug solubility, enhanced drug absorption and the long circulation time of the NM-loaded LPM could be promising to improve nasal and parenteral delivery of NM.
a Department of Labeled Compounds , Hot Labs. Center, Egyptian Atomic Energy Authority , Cairo , Egypt and.
Hassan M
HM
Rashed
b Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Cairo University , Cairo , Egypt.
Rehab N
RN
Shamma
b Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Cairo University , Cairo , Egypt.
Emad B
EB
Basalious
D000281:Administration, Intranasal; D000818:Animals; D001682:Biological Availability; D001812:Blood-Brain Barrier / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics; D004339:Drug Compounding; D005079:Excipients / Q000008:administration & dosage* / Q000737:chemistry; D006207:Half-Life; D007275:Injections, Intravenous; D051379:Mice; D008823:Micelles; D036103:Nanotechnology; D009553:Nimodipine / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D010316:Particle Size; D010713:Phosphatidylcholines / Q000008:administration & dosage* / Q000737:chemistry; D011060:Poloxalene / Q000008:administration & dosage / Q000737:chemistry; D020442:Poloxamer / Q000008:administration & dosage* / Q000737:chemistry; D012995:Solubility; D013667:Technetium; D014018:Tissue Distribution; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics
D002121:Calcium Channel Blockers; D004337:Drug Carriers; D005079:Excipients; D008823:Micelles; D010713:Phosphatidylcholines; D014665:Vasodilator Agents; D020442:Poloxamer; C464484:pluronic block copolymer P123; D009553:Nimodipine; D013667:Technetium; D011060:Poloxalene
Nimodipine; lipo-pluronic micelles; radiolabeling; subarachnoid hemorrhage